Har­row prices $60M of­fer­ing one day af­ter ac­quir­ing US, Cana­di­an rights to new dry eye treat­ment

Eye biotech Har­row Health is look­ing to raise $60 mil­lion af­ter buy­ing the rights to an eye prod­uct new­ly ap­proved by the FDA.

The com­pa­ny said Wednes­day that it would of­fer rough­ly 3.38 mil­lion shares of its stock at $17.75 each, giv­ing un­der­writ­ers an op­tion to buy an ad­di­tion­al 15%, or around 507,000 shares at that price. The of­fer­ing is sched­uled to close Fri­day.

Har­row said it plans to use the mon­ey to fund “the ini­tial amount payable for an ac­qui­si­tion.” What­ev­er is left over will like­ly be used to fund fu­ture ac­qui­si­tions or for work­ing cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER